Using arpraziquantel to treat schistosomiasis in preschool-aged children
Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Kenya and Côte d'Ivoire: A Small-scale Public Health Intervention Study Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Uganda, With Special Consideration of Dose Determination Methods: a Small-scale Public Health Intervention Study in Hoima and Bugiri Districts
This study is testing how well different ways of giving a new child-friendly medicine for schistosomiasis work for preschool-aged kids in Côte d'Ivoire, Kenya, and Uganda.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 18500 (estimated) |
| Ages | 24 Months to 59 Months |
| Sex | All |
| Sponsor | Swiss Tropical & Public Health Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 7 sites (Abidjan and 6 other locations) |
| Trial ID | NCT06698510 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the effectiveness of different platforms for distributing arpraziquantel, a child-friendly formulation of praziquantel, to preschool-aged children in Côte d'Ivoire, Kenya, and Uganda. The study focuses on children aged 24 to 59 months who are often overlooked in schistosomiasis treatment campaigns. It will assess coverage, feasibility, and acceptability of the drug delivery methods, as well as identify training and mobilization needs for effective implementation. The intervention is part of broader mass drug administration campaigns targeting schistosomiasis control.
Who should consider this trial
Good fit: Ideal candidates for this study are preschool-aged children aged 24 to 59 months living in designated implementation areas.
Not a fit: Patients with acute or chronic illnesses, those unable to take oral medication, or those with a history of seizures will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve schistosomiasis treatment coverage among preschool-aged children in endemic areas.
How similar studies have performed: Previous studies have shown success in using similar public health intervention strategies for mass drug administration in endemic regions.
Eligibility criteria
Show full inclusion / exclusion criteria
* Living in the designated implementation area since at least 6 months * Aged between 24 - 59 months * Informed consent available * No acute or chronic illness and/or inability to take oral medication * No reported history of seizures * No known allergic response to praziquantel
Where this trial is running
Abidjan and 6 other locations
- Programme National de Lutte Contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (MSHPCMU) — Abidjan, Côte d’Ivoire (Recruiting)
- Université Félix Hophouët-Boigny (UFHB), Département de sociologie — Abidjan, Côte d’Ivoire (Recruiting)
- Université Félix Hophouët-Boigny (UFHB), UFR Biosciences — Abidjan, Côte d’Ivoire (Recruiting)
- African Institute for Health and Development (AIHD) — Nairobi, Kenya (Not_yet_recruiting)
- Kenya Medical Research Institute (KEMRI), Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC) — Nairobi, Kenya (Not_yet_recruiting)
- Makerere University, Department of Sociology and Anthropology — Kampala, Uganda (Not_yet_recruiting)
- Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health — Kampala, Uganda (Not_yet_recruiting)
Study contacts
- Principal investigator: Peter Steinmann, PhD PD — Swiss Tropical & Public Health Institute
- Study coordinator: Peter Steinmann, PhD PD
- Email: peter.steinmann@swisstph.ch
- Phone: +41 61 284 82 18
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.